Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Corey J Langer

Showing results (61-70 of 225) with videos related to

Pageof 23
Sort By:
The Journal of Supportive Oncology|December 2, 2006
Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive modelRaymond S McDermott, Dwight D Kloth, Hao Wang, et al.
JAMA Oncology|April 15, 2021
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung CancerLova Sun, Miles Hsu, Roger B Cohen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 10, 2014
Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional surveyJoshua Bauml, Corey J Langer, Tracey Evans, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapiesFred R Hirsch, Giorgio V Scagliotti, Corey J Langer, et al.
Clinical Lung Cancer|May 5, 2010
Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experienceBinu Malhotra, Tracey Evans, Jared Weiss, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2005
Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?Corey J Langer, Jennifer Moughan, Benjamin Movsas, et al.
Journal of the National Cancer Institute|February 7, 2002
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trialCorey J Langer, Judith Manola, Patricia Bernardo, et al.
Cancer Investigation|January 12, 2005
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology GroupCorey J Langer, Yi Li, Timothy Jennings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911Corey J Langer, Jonathan Harris, Eric M Horwitz, et al.
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgeryCharu Aggarwal, Linna Li, Hossein Borghaei, et al.
Pageof 23

Showing results (61-70 of 225) with videos related to

Sort By:
Pageof 23
The Journal of Supportive Oncology|December 2, 2006
Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive modelRaymond S McDermott, Dwight D Kloth, Hao Wang, et al.
JAMA Oncology|April 15, 2021
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor-Based Therapy in Patients With Advanced Non-Small-Cell Lung CancerLova Sun, Miles Hsu, Roger B Cohen, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 10, 2014
Does perceived control predict Complementary and Alternative Medicine (CAM) use among patients with lung cancer? A cross-sectional surveyJoshua Bauml, Corey J Langer, Tracey Evans, et al.
Lung Cancer (Amsterdam, Netherlands)|July 18, 2003
Epidermal growth factor family of receptors in preneoplasia and lung cancer: perspectives for targeted therapiesFred R Hirsch, Giorgio V Scagliotti, Corey J Langer, et al.
Clinical Lung Cancer|May 5, 2010
Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experienceBinu Malhotra, Tracey Evans, Jared Weiss, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2005
Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?Corey J Langer, Jennifer Moughan, Benjamin Movsas, et al.
Journal of the National Cancer Institute|February 7, 2002
Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trialCorey J Langer, Judith Manola, Patricia Bernardo, et al.
Cancer Investigation|January 12, 2005
Phase II evaluation of 96-hour paclitaxel infusion in advanced (recurrent or metastatic) squamous cell carcinoma of the head and neck (E3395): a trial of the Eastern Cooperative Oncology GroupCorey J Langer, Yi Li, Timothy Jennings, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2007
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911Corey J Langer, Jonathan Harris, Eric M Horwitz, et al.
Cancer Control : Journal of the Moffitt Cancer Center|December 21, 2013
Multidisciplinary therapy of stage IIIA non-small-cell lung cancer: long-term outcome of chemoradiation with or without surgeryCharu Aggarwal, Linna Li, Hossein Borghaei, et al.
Pageof 23